IONS NASDAQ Week ended 07 Aug 2026

Weekly Investor Report

Ionis Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 56.56 USD
9.3% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -22.8% below the Trend Line and sits at 34.9% of its 52-week range. The latest completed week returned 9.3%, after a -2.9% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is bullish with 49/100 conviction, while the latest news-sentiment score is 46/100. Near-term considerations: volume confirmation is below normal.

Setup score 21 out of 100
Latest Close 56.56 USD 7 Aug 2026
1W Return 9.3% latest completed week
4W Return -2.9% short-term follow-through
12W Return -23.8% quarterly tape
Trend Breadth 59.6% 31 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 9.3% Latest completed week; four-week move -2.9%. Indicator stack 33/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Bullish 49/100 conviction; expected move 5.9%. News sentiment 46/100 57 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -22.8% below the Trend Line and sits at 34.9% of its 52-week range. The latest completed week returned 9.3%, after a -2.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3312-week average 0.34

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership2/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.33Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers44 reversal markers

No recent accumulation markers. 4 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.9% over four weeks, -23.8% over 12 weeks, and 35.8% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W9.3%
4W-2.9%
12W-23.8%
26W-34.6%
52W35.8%
Active trend streak0 weeks
Active weeks in one year31
Trend breadth59.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.04Latest activity-pressure read.
Pressure change-395.3%Four-week change in activity pressure.
Leadership-30.92Latest relative-leadership reading.
RS change-6.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 30 Jun 2026 Field coverage 85% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength12/100Blend of value, momentum, and quality. Underlying universe rank 89; rank 1 is best.
Value19/100Relative valuation strength. Underlying universe rank 82; rank 1 is best.
Quality8/100Profitability and accounting quality. Underlying universe rank 93; rank 1 is best.
Momentum71/100Medium-term price momentum. Underlying universe rank 30; rank 1 is best.
Growth18/100Revenue and earnings growth. Underlying universe rank 83; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
10.8x
Market value relative to trailing revenue.
EV / EBITDA
2.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-3.8%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.2%
Gross profit retained from each unit of revenue.
Operating margin
-57.4%
Operating profit retained from revenue.
Free-cash-flow margin
-49.7%
Free cash flow generated from revenue.
Return on invested capital
-15.0%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-7.4%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-2.8%
Net share repurchases relative to market value.
Shareholder yield
-2.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningBullish

IONS shows bullish options pressure with a 49/100 conviction score, put-call volume ratio of 0.05, expected move of 5.9%, and Sharemaestro trend signal inactive.

Conviction49/100
Expected move5.9%
Put/call volume0.05
Pressure97
Speculation12
Volatility58
Trend agreement0
Open options detail
Insider activity9 / 11

9 acquisitions and 11 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment46/100

Weighted news tone is neutral across 57 relevant articles.

16 positive · 26 neutral · 15 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move5.9%Nearest-chain priced movement where available.
52-week drawdown-34.8%Distance below the 52-week high.
13-week volatility9.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+9.5%Week of 26 Jun.
Worst week-28.8%Week of 10 Jul.
Latest week+9.3%Week of 7 Aug.

Shape of recent returns

Strong gains2
Modest gains12
Flat weeks0
Modest losses7
Sharp losses5
Recent vol9.3%13-week weekly-return volatility.
Base vol8.3%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew5.0% / -4.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape21/100

Trend, activity pressure, participation, and risk combine to a 21/100 tape read.

 Indicator analysis17/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 2/12.

Activity pressure 0.33; 4 reversal markers Factors24/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 80; Small Cap Core rank 81 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options46/100

IONS shows bullish options pressure with a 49/100 conviction score, put-call volume ratio of 0.05, expected move of 5.9%, and Sharemaestro trend signal inactive.

Bullish · Call-side pressure · Expected move 5.9% Sentiment46/100

Weighted news tone is neutral across 57 relevant articles.

How TRYNGOLZA Approval and New Equity Shelf At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story Insiders9 / 11

9 acquisitions and 11 disposals in the latest 180-day insider tape.

 Earnings50/100

No stored earnings event is currently attached to this ticker.

 Research flow1 items

0 recent research articles and 1 Market Watch posts are available.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202656.56 USD9.3%73.25 USD51.13 USD-1.04-30.9212.6MOff
31 Jul 202651.77 USD-8.5%74.05 USD51.03 USD-0.95-33.4914.0MOff
24 Jul 202656.55 USD4.0%74.98 USD50.95 USD-0.43-26.9820.9MOff
17 Jul 202654.39 USD-6.6%75.76 USD50.84 USD0.10-30.8019.8MOff
10 Jul 202658.25 USD-28.8%76.59 USD50.75 USD0.35-28.9338.7MOff
3 Jul 202681.80 USD0.8%77.35 USD50.65 USD0.461.698.9MOff
26 Jun 202681.18 USD9.5%77.34 USD50.40 USD0.072.4412.3MOff
19 Jun 202674.12 USD1.2%77.39 USD50.14 USD-0.41-10.038.1MOff
12 Jun 202673.28 USD-1.6%77.46 USD49.92 USD-0.56-8.229.0MOff
5 Jun 202674.48 USD-2.6%77.40 USD49.71 USD-0.79-3.998.1MOff
29 May 202676.50 USD1.2%77.37 USD49.49 USD-0.88-5.195.9MOff
22 May 202675.56 USD1.8%77.30 USD49.27 USD-0.84-2.989.6MOff
15 May 202674.23 USD-2.0%77.14 USD49.05 USD-0.96-2.848.2MOff
8 May 202675.71 USD0.6%77.10 USD48.82 USD-0.93-0.517.9MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context